NEW YORK/LONDON |
(Reuters) - Unlocking the potential of Genzyme's experimental multiple sclerosis drug Campath could be key to prying a higher price for the U.S. biotech from Sanofi-Aventis
Campath accounts for a chunk of Genzyme's market value already, but Wall Street sales projections vary widely.
Its role in Sanofi's $18.5 billion hostile bid for Genzyme came to the fore this week, when the French drugmaker gave its own estimate for Campath sales and left the door open to a higher deal price if given proof of the treatment's value.
"We identified this as one of the areas where we potentially had a valuation metric difference and this one would be a good area where we could do a little deeper dive," Sanofi Chief Executive Chris Viehbacher said after launching the hostile offer on Monday
Continue reading by clicking here
"Providing You with 'MS Views and News', is what we do"
Keep Informed and up-to-date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
0 comments:
Post a Comment